CoChat
Sign Up
Cited by 31

The DOI matches its Crossref record.

MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target

Zhang, Suwei, Zhang, Qiaoxin, Shi, Ganggang, Yin, Jun·2018·Biomedicine & Pharmacotherapy
DOI 10.1016/j.biopha.2017.11.002
Open this paper in CoChat — free account

Abstract

The importance of microRNAs (miRNAs) are shown during various cancers including acute myeloid leukemia (AML). MiR-182-5p functions as an oncogene or a potential suppressive miRNA in cancers, but its expression and function in AML is unknown. The purpose is to investigate the roles of miR-182-5p in AML in this study. MiR-182-5p was examined in the blood samples of AML and it was found that miR-182-5p expression levels were higher in AML tissues than it in their normal controls, so did in the AML cells. BCL2L12 and BCL2 were predicted as target genes of miR-182-5p and verified using luciferase reporter assay. BCL2L12 and BCL2 mRNA and protein levels were up-regulated in the AML cells with miR-182-5p inhibition. Cellular function of miR-182-5p indicated that miR-182-5p suppression in AML cells could decrease cell proliferation and reverse cisplatin (DDP) resistance via targeting BCL2L12 and BCL2 expression. Inhibition of miR-182-5p promoted AML cell apoptosis by targeting BCL2 or BCL2L12. The study demonstrates that high levels of miR-182-5p in AML promotes cell proliferation and suppresses cell apoptosis by targeting BCL2L12 and BCL2.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2017.11.002

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 25

  1. Estey, 2013, Acute myeloid leukemia: 2013 update on risk-stratification and management, Am. J. Hematol., 88, 318, 10.1002/ajh.23404 · DOI
  2. Marcucci, 2011, The prognostic and functional role of microRNAs in acute myeloid leukemia, Blood, 117, 1121, 10.1182/blood-2010-09-191312 · DOI
  3. Khalaj, 2014, Pathogenic microRNA’s in myeloid malignancies, Front. Genet., 5, 361, 10.3389/fgene.2014.00361 · DOI
  4. Zebisch, 2016, Therapeutic resistance in acute myeloid leukemia: the role of non-coding RNAs, Int. J. Mol. Sci., 17, 10.3390/ijms17122080 · DOI
  5. Liao, 2017, miRNAs in acute myeloid leukemia, Oncotarget, 8, 3666, 10.18632/oncotarget.12343 · DOI
  6. Sharifi, 2017, Apoptosis-inducing and antiproliferative effect by inhibition of miR-182-5p through the regulation of CASP9 expression in human breast cancer, Cancer Gene Ther.
  7. Xue, 2016, miR-182-5p induced by STAT3 activation promotes glioma tumorigenesis, Cancer Res., 76, 4293, 10.1158/0008-5472.CAN-15-3073 · DOI
  8. Yao, 2016, Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway, Biochem. Biophys. Res. Commun., 474, 213, 10.1016/j.bbrc.2016.04.107 · DOI
  9. Tsuchiyama, 2013, Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer, Prostate, 73, 827, 10.1002/pros.22626 · DOI
  10. Hirata, 2012, Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer, PLoS One, 7, e51056, 10.1371/journal.pone.0051056 · DOI
  11. Hirata, 2013, MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer, PLoS One, 8, e55502, 10.1371/journal.pone.0055502 · DOI
  12. Xu, 2014, Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway, Mol. Cancer, 13, 109, 10.1186/1476-4598-13-109 · DOI
  13. Delbridge, 2015, The BCL-2 protein family, BH3-mimetics and cancer therapy, Cell Death Differ., 22, 1071, 10.1038/cdd.2015.50 · DOI
  14. Tong, 2015, miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1, Biomed. Pharmacother., 75, 129, 10.1016/j.biopha.2015.07.036 · DOI
  15. Nishioka, 2015, The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells, Leukemia, 29, 2296, 10.1038/leu.2015.219 · DOI
  16. Chien, 2015, Differential roles of Bcl2L12 and its short variant in breast cancer lymph node metastasis, Oncol. Rep., 34, 961, 10.3892/or.2015.4071 · DOI
  17. Tzovaras, 2014, BCL2L12: a promising molecular prognostic biomarker in breast cancer, Clin. Biochem., 47, 257, 10.1016/j.clinbiochem.2014.09.008 · DOI
  18. Lee, 2013, Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12, Neoplasia, 15, 1262, 10.1593/neo.131184 · DOI
  19. Stegh, 2011, Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma, ABBV Cell Cycle, 10, 33, 10.4161/cc.10.1.14365 · DOI
  20. Stegh, 2010, Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor, Genes Dev., 24, 2194, 10.1101/gad.1924710 · DOI
  21. Hong, 2008, Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells, Biochim. Biophys. Acta, 1782, 649, 10.1016/j.bbadis.2008.09.008 · DOI
  22. Stegh, 2008, Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma, Proc. Natl. Acad. Sci. U. S. A., 105, 10703, 10.1073/pnas.0712034105 · DOI
  23. Kouri, 2015, miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma, Genes Dev., 29, 732, 10.1101/gad.257394.114 · DOI
  24. Stegh, 2007, Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma, Genes Dev., 21, 98, 10.1101/gad.1480007 · DOI
  25. Yan, 2012, Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2, PLoS One, 7, e40967, 10.1371/journal.pone.0040967 · DOI

Cited by

Metadata

Authors
Zhang, S., Zhang, Q., Shi, G., & Yin, J.
Venue
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Published
2018-01
Volume
97
Pages
1189-1194
ISSN
0753-3322
DOI
10.1016/j.biopha.2017.11.002
Cited by
31
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review